Neuromuscular Disorders
Volume 18, Issue 1 , Pages 19-26 , January 2008

Reliability of clinical outcome measures in Charcot-Marie-Tooth disease

  • A. Solari

      Affiliations

    • Neuroepidemiology Unit, IRCCS Foundation, “C. Besta” Neurological Institute, Via Celoria 11, 20133 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 2394 2391; fax: +39 02 7060 6233.
    • ,
  • M. Laurà

      Affiliations

    • Division of Biochemistry and Genetics, IRCCS Foundation, “C. Besta” Neurological Institute, Milan, Italy
    • ,
  • E. Salsano

      Affiliations

    • Division of Biochemistry and Genetics, IRCCS Foundation, “C. Besta” Neurological Institute, Milan, Italy
    • ,
  • D. Radice

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    • ,
  • D. Pareyson

      Affiliations

    • Division of Biochemistry and Genetics, IRCCS Foundation, “C. Besta” Neurological Institute, Milan, Italy
    • ,
  • On behalf of the CMT-TRIAAL Study Group

      Affiliations

    • See Appendix B.

Received 12 July 2007 ,Accepted 6 September 2007.

References 

  1. Martyn CN, Hughes RAC. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62:310–318
  2. Pareyson D, Scaioli V, Laurà M. Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. Neuromol Med. 2006;8:3–22
  3. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004;10:396–401
  4. Huxley C, Passage E, Manson A, et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet. 1996;5:563–569
  5. Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005;64:1209–1214
  6. Pareyson D, Schenone A, Fabrizi GM, et al. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol (EudraCT no:2006-000032-27). Pharmacol Res. 2006;54:436–441
  7. Reilly MM, de Jonghe P, Pareyson D. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A). 8–10 April 2005, Naarden, The Netherlands. Neuromuscul Disord 2006;16:396–402.
  8. Graham RC, Hughes RAC. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry. 2006;77:973–976
  9. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 2000;54:943–949
  10. Solari A, Radice D, Manneschi L, Motti L, Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci. 2005;228:71–74
  11. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehab. 1988;69:850–854
  12. Merlini L, Mazzone E, Solari A, Morandi L. Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve. 2002;26:64–70
  13. Merlini L, Solari A, Vita G, et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol. 2003;18:537–541
  14. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174
  15. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis. 1987;40:171–178
  16. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–428
  17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–317
  18. Svensson E, Häger-Ross C. Hand function in Charcot-Marie-Tooth: test–retest reliability of some measurements. Clin Rehab. 2006;20:896–908
  19. Kilmer DD, McCrory MA, Wright NC, Rosko RA, Kim HR, Aitkens SG. Hand-held dynamometry reliability in persons with neuropathic weakness. Arch Phys Med Rehab. 1997;78:1364–1368
  20. Selles RW, van Ginneken BT, Schreuders TA, Janssen WG, Stam HJ. Dynamometry of intrinsic hand muscles in patients with Charcot-Marie-Tooth disease. Neurology. 2006;67:2022–2027
  21. Hughes R, Bensa S, Willison H, et al. Inflammatory Neuropathy Cause and Treatment (INCAT) Group Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201
  22. Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA for the Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2002;72:596–601
  23. McMahon LM, Burdett LC, Whithey SL. Effects of muscle groups and placement site in reliability of hand-held dynamometry strength measurements. J Ortop Sports Phys Ther. 1992;15:236–241
  24. Philips BA, Lo SK, Mastaglia FL. Muscle force measured using “break” testing with a hand-held myometer in normal subjects aged 20 to 69 years. Arch Phys Med Rehab. 2000;81:653–661
  25. van der Ploeg RJ, Fidler V, Oosterhuis HJ. Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry. 1991;54:244–247

PII: S0960-8966(07)00723-7

doi: 10.1016/j.nmd.2007.09.006

Neuromuscular Disorders
Volume 18, Issue 1 , Pages 19-26 , January 2008

Article Tools

* Image Usage & Resolution